tetano
Editor, Senior Moderator
Antiviral Res
. 2023 Nov 18:105757.
doi: 10.1016/j.antiviral.2023.105757. Online ahead of print. Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization
Qiu-Yan Zhang[SUP] 1 [/SUP], Hong-Qing Zhang[SUP] 2 [/SUP], Ya-Nan Zhang[SUP] 1 [/SUP], Zhe-Rui Zhang[SUP] 1 [/SUP], Xiao-Dan Li[SUP] 3 [/SUP], Meng-Chan Hao[SUP] 2 [/SUP], Yang Zhang[SUP] 4 [/SUP], Jia-Qi Li[SUP] 2 [/SUP], Yan-Yan Hu[SUP] 2 [/SUP], Xiao-Ling Chen[SUP] 2 [/SUP], Jing Wang[SUP] 2 [/SUP], Yu-Jia Shi[SUP] 3 [/SUP], Cheng-Lin Deng[SUP] 1 [/SUP], Jian-Jun Chen[SUP] 2 [/SUP], Han-Qing Ye[SUP] 5 [/SUP], Bo Zhang[SUP] 6 [/SUP]
Affiliations
Despite global vaccination efforts, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve and spread globally. Currently, the development of affordable vaccine against Omicron variant of concern (VOC) is necessary. Here, we assessed the safety and immunogenicity of a SARS-CoV-2 vaccine consisting of a live Newcastle disease virus vector expressing the spike (S) protein of Omicron BA.1 administrated intranasally (IN) or intramuscularly (IM) in Golden Syrian hamster model. Immunogenicity studies showed that the prime-boost regimen elicited high antibody titers and the modified S antigen (Sm-F) could induce robust antibody response in low dosage immunization through IN route. Sera of the immunized hamsters provided effective cross-neutralizing activity against different Omicron variants, the prototype and delta strains of SARS-CoV-2. Moreover, the vaccine could provide complete immunoprotection in hamsters against the Omicron BA.1 challenge by either intranasal or intramuscular immunization. Overall, our study provides an alternative nasal vaccine against the SARS-CoV-2 Omicron variants.
Keywords: Intranasal immunization; NDV vector vaccine; Omicron variant.
. 2023 Nov 18:105757.
doi: 10.1016/j.antiviral.2023.105757. Online ahead of print. Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization
Qiu-Yan Zhang[SUP] 1 [/SUP], Hong-Qing Zhang[SUP] 2 [/SUP], Ya-Nan Zhang[SUP] 1 [/SUP], Zhe-Rui Zhang[SUP] 1 [/SUP], Xiao-Dan Li[SUP] 3 [/SUP], Meng-Chan Hao[SUP] 2 [/SUP], Yang Zhang[SUP] 4 [/SUP], Jia-Qi Li[SUP] 2 [/SUP], Yan-Yan Hu[SUP] 2 [/SUP], Xiao-Ling Chen[SUP] 2 [/SUP], Jing Wang[SUP] 2 [/SUP], Yu-Jia Shi[SUP] 3 [/SUP], Cheng-Lin Deng[SUP] 1 [/SUP], Jian-Jun Chen[SUP] 2 [/SUP], Han-Qing Ye[SUP] 5 [/SUP], Bo Zhang[SUP] 6 [/SUP]
Affiliations
- PMID: 37984567
- DOI: 10.1016/j.antiviral.2023.105757
Despite global vaccination efforts, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve and spread globally. Currently, the development of affordable vaccine against Omicron variant of concern (VOC) is necessary. Here, we assessed the safety and immunogenicity of a SARS-CoV-2 vaccine consisting of a live Newcastle disease virus vector expressing the spike (S) protein of Omicron BA.1 administrated intranasally (IN) or intramuscularly (IM) in Golden Syrian hamster model. Immunogenicity studies showed that the prime-boost regimen elicited high antibody titers and the modified S antigen (Sm-F) could induce robust antibody response in low dosage immunization through IN route. Sera of the immunized hamsters provided effective cross-neutralizing activity against different Omicron variants, the prototype and delta strains of SARS-CoV-2. Moreover, the vaccine could provide complete immunoprotection in hamsters against the Omicron BA.1 challenge by either intranasal or intramuscular immunization. Overall, our study provides an alternative nasal vaccine against the SARS-CoV-2 Omicron variants.
Keywords: Intranasal immunization; NDV vector vaccine; Omicron variant.